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RNA viruses evolve rapidly. One source of this ability to rapidly
change is the apparently high mutation frequency in RNA virus
populations. A high mutation frequency is a central tenet of the
quasispecies theory. A corollary of the quasispecies theory postu-
lates that, given their high mutation frequency, animal RNA viruses
may be susceptible to error catastrophe, where they undergo a
sharp drop in viability after a modest increase in mutation fre-
quency. We recently showed that the important broad-spectrum
antiviral drug ribavirin (currently used to treat hepatitis C virus
infections, among others) is an RNA virus mutagen, and we
proposed that ribavirin’s antiviral effect is by forcing RNA viruses
into error catastrophe. However, a direct demonstration of error
catastrophe has not been made for ribavirin or any RNA virus
mutagen. Here we describe a direct demonstration of error catas-
trophe by using ribavirin as the mutagen and poliovirus as a model
RNA virus. We demonstrate that ribavirin’s antiviral activity is
exerted directly through lethal mutagenesis of the viral genetic
material. A 99.3% loss in viral genome infectivity is observed after
a single round of virus infection in ribavirin concentrations suffi-
cient to cause a 9.7-fold increase in mutagenesis. Compiling data on
both the mutation levels and the specific infectivities of poliovirus
genomes produced in the presence of ribavirin, we have con-
structed a graph of error catastrophe showing that normal polio-
virus indeed exists at the edge of viability. These data suggest that
RNA virus mutagens may represent a promising new class of
antiviral drugs.
The rapid evolution of RNA viruses is apparently powered bythe high mutation frequency in RNA virus populations
(1–6). The high mutation frequency of animal RNA viruses has
been primarily inferred from genetic markers, and such assays
may not be accurate enough to establish the exact mutation
frequencies. Here we report data defining the high mutation
frequency of poliovirus, a model RNA virus, and then we
proceed to examine the implications of that high mutation
frequency regarding mutagenic antiviral drug interventions that
might exploit the high mutation frequency to destroy the virus.
The quasispecies theory states that an RNA virus population
does not consist of a single ‘‘wild-type’’ genotype but instead is
an ensemble of related genotypes (7–11). This quasispecies is
then capable of very rapid evolution in new environments
because of the large number of potentially beneficial mutations
already present within the population. Maintaining such a high
mutation frequency, however, is dangerous for the virus. There
is an intrinsic limit to the maximum variability of viral genetic
information before it loses meaning (7, 12), and if an RNA virus
quasispecies goes beyond that mutation limit, the population will
no longer be viable. The phenomenon that occurs when the loss
of genetic fidelity results in a lethal accumulation of errors has
been termed ‘‘error catastrophe’’ (Fig. 1) (3, 7). Most cellular
organisms have evolved a number of sophisticated processes to
maintain their genetic information with high fidelity and stay far
away from the threshold of error catastrophe. In contrast, it has
been predicted that RNA viruses with high mutation frequencies
exist close to the edge of error catastrophe and can be forced into
error catastrophe by a moderate increase in mutation rate.
Several indirect lines of evidence have been presented that
support the existence of such an error catastrophe (13–17).
Our recent study demonstrated that the important broad-
spectrum antiviral drug ribavirin [currently used clinically to
treat hepatitis C virus (18, 19), respiratory syncytial virus (20),
and lassa fever virus infections (21)] is an RNA virus mutagen
(15). In that study, we observed a direct correlation between the
mutagenic effect of ribavirin and the reduction of poliovirus
titers, suggesting that ribavirin exerts its antiviral activity by
lethally mutagenizing the virus population. However, a direct
demonstration of error catastropheylethal mutagenesis has not
been made for ribavirin or any RNA virus mutagen. That is to
say, no study has provided direct proof that the antiviral effect
of any drug is exerted via its mutagenic effects on the viral
genetic material and not via secondary effects of the drug on
cellular physiology or viability, or via inhibition of other aspects
of the virus life cycle.
Here we demonstrate that ribavirin’s antiviral activity is
exerted through lethal mutagenesis, specifically destroying the
infectivity of the poliovirus genomic RNA. We also describe
direct evidence that the error catastrophe theory applies to
poliovirus. Compiling data from experiments that use increasing
levels of ribavirin mutagenesis, we are able to establish the
relationship between mutation frequency and virus viability,
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Fig. 1. Model of error catastrophe. The majority of viruses in a normal
picornavirus population are viable (51). But a small increase in mutation
frequency is predicted to push the virus population into error catastrophe (the
mutagenized population, Right), where the number of errors per viral ge-
nome is sufficiently high to lethally mutate a majority of the virus population.
White indicates live virus, gray indicates dead virus. Most animal RNA virus
genomes are '10 kb long.




























showing a strikingly precipitous drop in virus viability at muta-
tion levels only slightly higher than normal.
Materials and Methods
Cells and Viruses. Human HeLa cells were propagated as previ-
ously described (15). All viral infections were performed by using
a poliovirus stock grown from a plasmid clone-derived Mahoney
strain poliovirus (pXpA). Inhibition of viral growth by ribavirin
(1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was done in
3–12 3 106 HeLa cells in OptiMEM 1 2% dialyzed FCS. Cells
were pretreated with high-grade ribavirin for 15 h (kindly
provided by Z. Hong, Schering–Plough) before infection, as
previously described (15). Note that ribavirin obtained from
Sigma is not sufficiently pure for in vivo experiments, as it causes
significant toxicity at high concentrations (data not shown).
Infections were done at a multiplicity of infection of 1–2.
RNA and virus were harvested at the time point of maximum
RNA accumulation (6 h postinfection for 0 and 100 mM ribavirin
and 10 h postinfection for 400 mM and 1,000 mM ribavirin). At
time of harvest, cells and supernatant for each condition were
divided into two equal samples, one half being the virus sample
and the other half for RNA extraction. Virus samples were
frozen for later analysis. PolyA1 RNA samples containing the
viral genomes were collected from cytoplasmic lysates by using
oligo dT25 DynaBeads (Dynal A.S., Oslo). RNA and virus stocks
from a single series of harvests were used in the experiments
reported in the presence of ribavirin, for internal consistency.
Similar data were obtained by using additional RNA and virus
stocks generated in the presence of ribavirin on additional days,
although sequencing of those stocks was not performed (data not
shown).
Quantification of reduction in total poliovirus RNA at each
condition (Fig. 2A; Table 2) was normalized to the number of
HeLa cells harvested in each condition [previously published
experiments normalized to 18S rRNA (15)]. RNA was quantified
three separate times, and the average is reported in Table 2.
Total poliovirus titers (Table 2) were determined by plaque
assay, as previously described (22). RNA infectivity (Figs. 3 and
4A) was determined by infectious center plaque assay, where the
amount of RNA indicated at each data point (Figs. 2B and 4A)
was electroporated into 1.2 3 106 HeLa cells. Electroporated
cells were serially diluted, and each series of dilutions was added
to a series of 10-cm plates of 50% confluent HeLa cells, allowed
to adhere for 2 h, then overlaid with mediumyagar and incubated
at 37°C, 7% CO2 for 48 h before staining the plates and counting
plaques, by using techniques previously described (23). A series
of control experiments were done to confirm that plaque for-
mation after cell electroporation was linear with cell dilution,
RNA concentration, and RNA infectivity (data not shown).
Molecular Biology. In vitro-transcribed poliovirus was generated
by using T7 RNA polymerase, as previously described (23), on
a pMoRA template [pXpA modified by a 59 ribozyme and long
39 polyA (24)]. Plasmid DNA was destroyed by DNaseI (Ambion,
Austin, TX) treatment at 37 for 309, and RNA was then
precipitated with 5 M LiCl to eliminate any possible DNA
contamination. Purity of all RNA samples (either in vitro tran-
scribed or isolated from polio-infected cells) was confirmed by
a negative PCR for poliovirus capsid DNA (data not shown).
Oligo dT primed cDNA was synthesized from 0.4 mg RNA from
the appropriate source (T7 transcripts, normal viral RNA, or
ribavirin-treated RNA) by using Superscript II (Life Technolo-
gies, Grand Island, NY), and VP1-coding sequence was PCR
amplified from 1y10th of the cDNA by using high fidelity
PfuTurbo polymerase (Stratagene) in a 25-cycle reaction. The
VP1 gene was cloned, and plasmid DNA was prepared from
independent bacterial colonies. All DNA sequencing (Tables 1
and 3) was done from position 2625–3400 of the poliovirus
genome by using BigDye terminator cycle sequencing (Applied
Biosystems) and then analyzed with DNASTAR SEQMANII (15).
Sequence analysis of 23 (approximately half) of the normal
poliovirus clones was published previously (15). Statistical anal-
ysis of significance (P values) of sequence data was done by
Student’s t test. Plus or minus ranges indicated for sequence data
are estimated at double (0.41 errorsy104 nt) the frequency of
reverse transcription–PCR (RT-PCR)-introduced errors deter-
mined in Results (0.21 errorsy104 nt).
Results
Mutation Frequencies in Normal Poliovirus Populations and in Vitro-
Generated Genomes. One source of the impressive ability of RNA
viruses to evolve is the apparently high mutation frequency in
RNA virus populations. However, it has been argued that the
available data do not accurately establish the mutation frequen-
cies of animal RNA viruses, and the true mutation frequencies
may be as low as 1026 (25, 26). Most estimates of high RNA virus
mutation frequencies have been based on genetic assays (1, 6,
27–34), which could give inaccurate estimates if the phenotypes
are not completely tight. For example, the mutation frequency
Fig. 2. Direct antiviral effect of ribavirin on the viral genetic material. (A)
Total poliovirus genomic RNA accumulation in infected cells, with and without
ribavirin. On the Left, normal poliovirus genomic RNA (Mo) isolated from
infected cells is normalized to a known quantity (100 ng) of in vitro-generated
poliovirus genomes (TRX). On the Right, quantities of poliovirus genomic RNA
isolated from infected cells in 100 mM ribavirin (Mo100r), 400 mM ribavirin
(Mo400r), and 1,000 mM ribavirin (Mo1000r), are normalized to amounts of
poliovirus genomic RNA from infected untreated cells (Mo). Comparisons are
tabulated in Table 2. (B) Large reductions in specific infectivity of ribavirin
mutagenized RNA virus genomes. Genomic poliovirus RNA from (■) untreated
cells, (F) 100 mM ribavirin-treated cells, (Œ) 400 mM ribavirin-treated cells, and
(l) 1,000 mM ribavirin-treated cells was tested for specific infectivity in a series
of infectious center assays. Data are shown with a linear curve fit for each
series. Assays were performed multiple times; data from a representative
experiment is shown.




















of poliovirus has been estimated at 2.1 3 1024 by scoring for the
presence of a single nucleotide mutation that confers a loss of
dependence on guanidine (1). In that poliovirus strain, guani-
dine is necessary for poliovirus replication, but if that block is not
absolute and the virus is capable of synthesizing '100 new
genomes in the absence of guanidine (instead of the normal
100,000 copies), the genetic marker would be overestimated in
the population by 1003 and the true mutation frequency would
be 2 3 1026, not 2 3 1024. Therefore, direct molecular evidence
(sequencing data) is necessary to precisely determine the mu-
tation frequency.
As the mutation frequency is a basic parameter of RNA virus
genetics, it is important to clearly establish this parameter.
Therefore, we set out to determine the mutation frequency in a
poliovirus population by analyzing capsid gene sequences from
a group of poliovirus clones. Poliovirus RNA was isolated from
infected cells, and 55 independent poliovirus cDNA clones were
obtained. Those poliovirus cDNAs were generated from viral
RNA by RT-PCR. As it was important to determine the number
of mutations introduced during the RT-PCR reactions, we first
performed a background control experiment where we se-
quenced the capsid VP1 genes of 58 cDNA clones generated by
RT-PCR reactions by using as templates in vitro generated
poliovirus genomes transcribed from a plasmid. We sequenced
a total of 48,000 nt from the background control clones and
observed an RT-PCR mutation frequency of 0.21 per 10,000 nt
(Table 1). Then we analyzed the capsid VP1 gene sequences
derived from the 55 independent normal poliovirus clones. We
sequenced a total of 42,000 nt of clones from a normal poliovirus
population and observed a mutation frequency of 2.1 per 10,000
nt (Table 1), well above the background level (P , 0.006).
Direct Antiviral Effect of Mutagenesis. Having established the high
mutation frequency of a normal poliovirus population, we set
out to test whether the virus exists near the threshold of error
catastrophe. Several studies have shown a correlation between
increased concentration of mutagen and loss of viral titer (13,
15–17) but not a direct demonstration that the antiviral effect
was exerted via the mutagenesis of the viral RNA genetic
material. The loss of titer could be because of inhibition of other
virus processes (i.e., translation or RNA packaging) or because
of secondary effects on cellular physiologyyviability.
Fig. 3. Distribution of mutations found in the VP1 capsid gene without
ribavirin (D), with 400 mM ribavirin mutagenesis (*), and 1,000 mM ribavirin
mutagenesis (l). Note that there are no particular mutational hotspots.
Almost all mutations at Cs were C3U and mutations at Gs were G3A. Also
note that in the presence of 400 mM ribavirin an unusual 3 nt deletion
(indicated by —) was detected at a CCA sequence.
Fig. 4. (A) Specific infectivity of T7 transcribed poliovirus genomes compared
with natural poliovirus genomes. This illustrates that between 0.21 and 2.1
mutations per 10,000 nt (Table 1), there is no significant detrimental effect on
the viability (specific infectivity) of poliovirus genomes. In vitro-transcribed
RNA (■); natural poliovirus RNA (F). Average data set is shown. (B) Relation-
ship of mutation frequency to genomic RNA infectivity. Specific infectivity of
normal poliovirus RNA was set to 100%. The graph shows that poliovirus
populations exist near the edge of error catastrophe, as there is a rapid decline
in RNA genome infectivity at levels of mutagenesis only slightly higher than
normal. The LI50 (50% loss of specific infectivity) is defined as the mutation
frequency at which 50% of the viral genomes are lethally mutated, indicated
by the dashed line. Wild-type (wt or Mo) poliovirus genomes contain an
average '1.5 mutationsygenome, based on data from Table 1. Poliovirus
genomes from cells treated with 100 mM ribavirin (Table 3) contain an average
'1.9 mutationsygenome. Poliovirus genomes from cells treated with 400 mM
ribavirin (Table 3) contain an average '6.9 mutationsygenome. Poliovirus
genomes from cells treated with 1,000 mM ribavirin (Table 3) contain an
average '15.5 mutationsygenome.




RT-PCR background control 0 0.21 0.21
Normal poliovirus
population 1.88 0.24 2.12
*Mutations per 10,000 nt sequenced.




























We recently demonstrated that ribavirin is an RNA virus
mutagen (15). Here we have now carried out experiments
designed to prove that lethal mutagenesis is the mechanism of
action of ribavirin. We infected cells with poliovirus in the
presence or absence of ribavirin. At the time point of maximum
viral RNA replication, we measured viral titer by plaque assay
and also isolated viral RNA. The amount of infectious virus
produced was reduced 3.2-fold by 100 mM ribavirin, 71-fold by
400 mM ribavirin, and 2,000-fold by 1,000 mM ribavirin. Addi-
tionally, we quantified the amount of viral RNA isolated from
infected cells in each condition by spectrophotometry and gel
electrophoresis of purified viral RNA (Fig. 2 A).
The specific infectivity of the poliovirus genomic RNA was
then determined for each condition by transfection of isolated
poliovirus genomic RNA into HeLa cells. Specific infectivity of
genomic viral RNA is a direct measure of genome viability.
Natural poliovirus genomic RNA had a specific infectivity of
1.5 3 106 plaque-forming units (PFU) per microgram genomes
(Fig. 2B). Poliovirus RNA from cells treated with 100 mM
ribavirin had a specific infectivity of 4.6 3 105 PFUymicrogram
genomes, a 3.3-fold reduction from wild-type levels. Poliovirus
RNA from cells treated with 400 mM ribavirin had a specific
infectivity of 8.4 3 104 PFUymicrogram genomes, an 18-fold
reduction from wild-type levels. Poliovirus RNA from cells
treated with 1,000 mM ribavirin had a specific infectivity of 1.1 3
104 PFUymicrogram genomes, a 140-fold reduction from wild-
type levels, indicating that fewer than 1% of the viral genomes
produced in the presence of 1,000 mM ribavirin were viable.
These data demonstrate that treatment with ribavirin has a
potent direct effect on the viral genetic material.
Strikingly, the full antiviral effect of ribavirin can be attributed
to lethal mutagenesis of the viral genetic material. In the
presence of 100 mM ribavirin, there was a 3.3-fold reduction in
genome viability (Fig. 2B, Table 2), which can fully account for
the 3.2-fold inhibition of infectious poliovirus titer (Table 2). In
the presence of 400 mM ribavirin, there was an 18-fold reduction
in genome viability (Fig. 2B, Table 2). Additionally, there was a
6-fold reduction in total genomic RNA (Fig. 2 A, Table 2), which
was likely due to the inactivation of many replicating viral
genomes in the ribavirin-treated cells during the multiple rounds
of replication and mutagenesis occurring in a single infectious
cycle. The combined effects of the mutagen on loss in genome
viability (18-fold) and reduction in genomic RNA production
(6-fold) would result in an anticipated total reduction in infec-
tious virus titer of '100-fold, which indeed accounts for the full
loss of titer observed (71-fold; Table 2). In the presence of 1,000
mM ribavirin, there was a 140-fold reduction in genome viability
(Fig. 2B; Table 2). Also there was a 16-fold reduction in total
genomic RNA (Fig. 2 A; Table 2), which again was likely due to
the inactivation of many replicating viral genomes in the riba-
virin-treated cells during the infectious cycle. The combined
total of the loss in genome viability (140-fold) and the reduction
in genomic RNA (16-fold) would result in an anticipated total
reduction in infectious virus titer of '2,200-fold because of the
direct effects of mutagenesis, which can account for the full loss
of titer observed (2,000-fold; Table 2).
Poliovirus Replicates at the Edge of Error Catastrophe. DNA copies
of viral RNA from each mutagen condition were sequenced to
determine the increase in mutation frequency caused by riba-
virin. The mutation frequency was increased 1.2-fold (60.2) in
the presence of 100 mM ribavirin, 4.4-fold (60.2) in the presence
of 400 mM ribavirin, and 9.7-fold (60.1) in the presence of 1,000
mM ribavirin (Table 3). A wide range of G3A and C3T
mutations were observed in the region sequenced, indicating
that the clones were obtained independently (Fig. 3). In addition,
G3A mutations are predicted to be induced by incorporation of
ribavirin triphosphate as a GTP nucleoside analog during pos-
itive strand RNA synthesis, whereas C3T mutations are pre-
dicted to be the result of ribavirin incorporation during negative
strand synthesis (15).
Plotting the data obtained above as genome infectivity versus
the average number of errors per poliovirus genome would
provide a graph of error catastrophe. To construct this graph, we
first determined the effect of a lower than normal mutation
frequency on poliovirus specific infectivity. The specific infec-
tivity of in vitro synthesized T7 genomic poliovirus transcripts,
which have low (0.2 3 1024ynt) mutation levels, is comparable
to that of natural poliovirus RNA (Fig. 4A). With the inclusion
of that data, we then constructed a graph of error catastrophe
based on our experimental observations (Fig. 4B). The graph
illustrates several interesting features of the relationship be-
tween mutation levels and virus RNA genome viability. First,
there is no significant detrimental effect on the viability of
poliovirus genomes at the normal mutation frequency ('10% in
this particular experiment). Therefore, the poliovirus genetic
information is f lexible enough to absorb up to an average of '1.5
mutations per genome without significant loss of function.
Strikingly, a small increase in mutation frequency above the
normal levels results in a large decline in viral infectivity (Fig.
4B). The LI50 (50% loss of infectivity), defined as the mutation
frequency at which 50% of the viral genomes are lethally
mutated, of poliovirus is '2.0 mutations per genome, less than
2-fold higher than the natural mutation frequency. Furthermore,
95% of the genomes are lethally mutated when there is a 4-fold
increase in mutation frequency. Thus, we conclude that the virus
has evolved to exist near the edge of error catastrophe.
Discussion
The error catastrophe theory has existed as a corollary of the
RNA virus quasispecies theory for over 20 years, and several
groups have previously published intriguing evidence that error
catastrophe can occur in RNA virus populations (13–17). By
using a potent RNA virus mutagen, ribavirin, here we have
provided molecular evidence that poliovirus mutation frequen-
cies are high ('2.1 3 1024), and we have described a direct
molecular demonstration that error catastrophe occurs and can
be used as an effective antiviral strategy.
Table 2. The antiviral effects of ribavirin can be directly








RNA-specific infectivity loss — 3.3 18 140
Loss of total viral RNA — — 6 16
Total predicted titer
reduction 1 3.3 100 2,200
Actual titer reduction* 1 3.2 71 2,000
*Untreated (‘‘normal’’) poliovirus titer in this experiment was 1.2 3 1010 PFU
per plate of HeLa cells (6 3 106 cells). Data are the average of three
experiments.
Table 3. Mutation frequency in ribavirin-treated RNA
virus populations
G3A C3T Total mutation frequency*
Normal population 0.5 1.2 2.1
100 mM ribavirin — 1.3 2.5
400 mM ribavirin 4.4 5.0 9.3
1,000 mM ribavirin 6.8 12.0 20.8
*Mutations per 10,000 nt sequenced.




















Mutation Frequencies. A variety of genetic markers have been used
to estimate the mutation frequencies of different RNA viruses.
Given that the mutation frequency is a basic parameter of RNA
virus genetics, it was valuable to firmly establish the mutation
frequency of a model RNA virus, poliovirus, at the molecular
level. We therefore carried out extensive sequence analysis of
natural poliovirus genomes and background control in vitro-
generated genomes, and we have established that the mutation
frequency is quite high, '2.1 3 1024. Using a different virus
(FMDV), Domingo’s group has recently published similar se-
quencing data (17), with an estimated mutation frequency of
2.8–5.9 3 1024. Although in that paper the frequency of reverse
transcription and PCR errors was not determined, because they
used experimental techniques similar to those used in this paper,
the RT-PCR background control data presented here (Table 1)
can probably be considered a reasonably accurate estimate of the
RT-PCR induced mutations expected to be present in their
FMDV study. Therefore the FMDV mutation frequencies pub-
lished by Domingo’s group should be an accurate representation
of the true mutation frequency. In both cases, the ability to
sustain a 2.1–5.9 3 1024 mutation frequency in virus populations
of greater than 109 PFUyml clearly depends on viral genomes
that have evolved to consist of highly flexible genetic information.
Parvin et al. published data in 1986 that are in apparent
contradiction to the poliovirus mutation frequency data we
present here, as they stated that they observed no mutations of
95,000 nt sequenced from 105 poliovirus VP1 gene clones (25).
However, Parvin et al. stated in their methods section that, by
using the traditional Sanger dideoxy DNA sequencing tech-
nique, they were uncertain about mutations at 320 sites in the
poliovirus clones (25). Even if only 10% of those 320 ‘‘uncertain’’
sites were true mutations, the data of Parvin et al. would be very
similar to ours, and therefore we suggest that any apparent
discrepancy between the two studies can likely be dismissed by
simply accounting for our use of the more accurate fluorescent
dye sequencing techniques now available.
Our 2.1 3 1024 mutation frequency estimation by sequence
analysis corroborates much of the available genetic marker-
based literature on animal RNA virus mutation frequencies (3,
8). Therefore, genetic markers can be considered reasonable
tools for estimating RNA virus mutation frequencies. In our
study, the majority of natural mutations observed were transition
mutations (C3U or G3A, Table 1). Genetic marker data are
consistent with this observation, as genetic markers scoring for
specific transitions were observed at high frequencies in several
independent studies [3 3 1025 (15), 2 3 1024 (1), 2 3 1025 (32)],
whereas a defined transversion event (A3C) was rarely detected
in another study (26).
Error Catastrophe. Ribavirin is an antiviral drug that is currently
in widespread clinical use to treat hepatitis C, respiratory
syncytial virus, and lassa fever virus infections (18–21). The
mechanism of action of ribavirin has been unclear since its
discovery almost 30 years ago (20, 35–39). We previously
proposed that ribavirin’s antiviral activity is exerted through its
potent RNA virus mutagenesis, as a nucleoside analog that
becomes incorporated into newly synthesized genomes by the
viral RNA-dependent RNA polymerase (15). Here we provide
molecular proof that ribavirin exerts its antiviral action directly
on poliovirus’s genetic material, lethally mutating the viral RNA
genome (Fig. 2B). Most strikingly, ribavirin’s mutagenic activity
can fully account for its antiviral effect against poliovirus
(Table 2).
Ribavirin’s overall antiviral effect is the result of the combined
effect of two components: a loss in specific infectivity of the viral
genomes because of lethal mutagenesis, and a loss in total viral
genomic RNA produced. We propose that the smaller of the two
effects, the reduction in viral RNA accumulation, is also caused
by the extensive drug-induced viral mutagenesis, resulting in very
few of the viral RNAs produced in the presence of ribavirin
remaining viable for replication. Within a single infectious cycle,
the viral RNA genomes must go through multiple rounds of
replication. Given that fewer than 1% of the total genomes
produced in an infected cell are themselves infectious (in the
presence of 1,000 mM ribavirin), the limited pool of genomes
competent for replication within the infected cell will surely
result in a reduction in total RNA genome accumulation, which
is indeed seen in our experiments. However, it is possible that
some of the loss in total genomic RNA is because of other effects
of ribavirin in the cells, such as the 2-fold inhibition of translation
(15) or ribavirin’s cytostatic effects. Nevertheless, the majority of
ribavirin’s antiviral effect, and possibly all of the antiviral effect,
is directly attributable to the lethal mutagenesis of the viral
genomes.
Animal RNA viruses have been hypothesized to maintain
themselves at the edge of error catastrophe (13). Fig. 4B maps
the relationship between mutation frequency and virus genome
viability. The graph illustrates that poliovirus appears to have
evolved to exist near the edge of error catastrophe, as small
increases in mutation frequency above the normal levels results
in a striking decline in viral infectivity, with a greater than 95%
loss in genome infectivity after a 4-fold increase in mutagenesis.
Existing at the edge of error catastrophe is predicted to optimize
the evolutionary fitness of the RNA virus quasispecies popula-
tion by maximizing genetic variation without sacrificing viability
(40). The data presented here demonstrate that high genetic
variability, a biological property that is normally a major advan-
tage for an RNA virus, can be turned into a weapon against the
virus by increasing that mutation rate beyond tolerable levels and
causing a genetic meltdown.
Unlike RNA viruses, DNA-based organisms generally have
much lower mutation frequencies and do not exist near the error
threshold. They appear to be able to absorb 300- to 5,000-fold
higher increases in mutation frequencies before significant loss
of viability is seen (41, 42), although DNA viruses may be an
exception (3, 42).
Implications for Antiviral Strategies. Ribavirin’s activity as a nu-
cleoside analog incorporated by the viral polymerase can explain
the surprisingly broad spectrum action of ribavirin against
members of almost all RNA virus families under laboratory cell
culture conditions (39) (and clinical activity against three virus
infections from diverse families), as the one common feature of
RNA viruses is they possess an RNA-dependent RNA polymer-
ase. A high mutation frequency and a susceptibility to error
catastrophe also appear to be common traits of most RNA
viruses (3, 8, 40). The experiments reported here used ribavirin
concentrations in the range of 100–1,000 mM, comparable to
concentrations observed in clinical settings (15, 36, 43). The
effectiveness of ribavirin in vivo as an RNA virus mutagen may
depend on the accumulation of ribavirin and ribavirin triphos-
phate in some tissues (such as liver, or respiratory tract epithe-
lium when administered as an aerosol) but not others. Alterna-
tively, differences in efficacy may be due to different rates of
ribavirin incorporation by the RNA-dependent RNA poly-
merases of different viruses; or ribavirin may have different
mechanisms of actions against different viruses (44, 45).
Ribavirin’s lethal mutagenesis of poliovirus is probably en-
hanced by the well-characterized ability of ribavirin monophos-
phate to inhibit the cellular enzyme inosine monophosphate
dehydrogenase (IMPDH) and thereby decrease cellular GTP
pools (46–48). The decrease in cellular GTP pools likely in-
creases the frequency of ribavirin incorporation as a mutagenic
GTP analog.
Several RNA virus mutagens are known, but they generally
exhibit substantial cellular toxicity (as nucleoside analogs pre-




























sumably incorporated by cellular DNA and RNA polymerases)
and are unacceptable for use in humans at the necessary doses
(13, 14, 49, 50). Therefore, in the interest of developing new
antiviral drugs that potentially exhibit activity against various
RNA virus human pathogens, it may be possible to identify
mutagenic nucleoside analogs that are highly specific for incor-
poration by viral RNA-dependent RNA polymerases. Such a
drug development strategy should be plausible given the success
in identifying and developing nucleoside analog anti-HIV ther-
apies that are capable of specifically inhibiting that virus’s
RNA-dependent DNA polymerase.
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